Efficacy and safety of early supplementation with 800 IU of vitamin D in very preterm infants followed by underlying levels of vitamin D at birth

Table 3 Secondary outcome variables at 32 and 36 weeks postmenstrual age

Variable	Cord 25(OH)D concentrations <10 ng/mL (N = 20)	Cord 25(OH)D concentrations ≥10 ng/mL (N = 29)	P
At birth
Serum calcium, mg/dL	7.0 ± 0.7	7.3 ± 0.8	0.12
Serum phosphorus, mg/dL	5.0 ± 1.4	4.8 ± 1.4	0.51
Serum ALP, IU/L	205.6 ± 63.7	178.8 ± 49.1	0.10
32 ± 1 weeks PMA
Serum calcium, mg/dL	9.7 ± 0.5	9.4 ± 0.7	0.86
Serum phosphorus, mg/dL	5.9 ± 0.9	5.2 ± 0.8	0.13
Serum ALP, IU/L	366.5 ± 102.3	422.0 ± 138.5	0.05
Serum PTH, pg/mL ^*	76.3 ± 50.1	74.2 ± 69.1	0.92
Vitamin D excess (>80 ng/mL)	0	0	-
36 ± 1 weeks PMA
Serum calcium, mg/dL	9.7 ± 0.4	9.7 ± 0.6	0.51
Serum phosphorus, mg/dL	6.2 ± 0.6	5.7 ± 1.9	0.07
Serum ALP, IU/L	284.6 ± 91.6	338.8 ± 127.1	0.11
Vitamin D excess (>80 ng/mL)	0/17	3/26	0.27
UCa/Cr	0.13 ± 0.16	0.19 ± 0.28	0.50
UCa/Cr >0.8	0	1 (3%)	1.00
Nephrocalcinosis, n	1 (5%)	2 (7%)	1.00
Weight, g	1881.1 ± 254.1	1813.2 ± 331.3	0.44
Length, cm	41.3 ± 1.5	40.5 ± 2.2	0.19
Head circumference, cm	30.6 ± 1.2	29.6 ± 1.4	0.43
BMC, g^†	2.6 ± 2.0	2.1 ± 1.7	0.44
BMD, g/cm^†	0.11 ± 0.02	0.10 ± 0.02	0.63

Data are presented as n (%), median (range), or mean ± SD unless otherwise indicated. -, could not be estimated because the data is skewed or categorical, or there are no events in both the groups
ALP alkaline phosphatase, PMA postmenstrual age, PTH parathyroid hormone, BMC bone mineral content, BMD bone mineral density
^* n = 18 and 20 in the cord 25(OH)D concentration < 10 ng/mL and ≥ 10 ng/mL groups, respectively
^† n = 12 and 19 in the cord 25(OH)D concentration < 10 ng/mL and ≥ 10 ng/mL groups, respectively

ISSN: 1824-7288